Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.

about

Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.

Item

http://www.wikidata.org/entity/Q43903971

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.

@en

type

Item

label

Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.

@en

prefLabel

Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.

@en

P1476

Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour

@en

P2093

Ajay P Belgaumkar

http://www.w3.org/2001/XMLSchema#string

Bruno Lorenzi

http://www.w3.org/2001/XMLSchema#string

Satvinder Mudan

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Tumor volume as an alternative response measurement for imatinib treated GIST patients.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

P304

E1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ANS.12195

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ferdinando Carlo Maria Cananzi

P577

2013-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23647808

http://www.w3.org/2001/XMLSchema#string